President Donald Trump and other administration officials are claiming credit for a recent drop in prescription drug prices, citing deals they’ve struck with drugmakers and the launch of the online direct-to-consumer platform TrumpRx. But experts are skeptical those measures have had much impact on prices overall, and they say other factors likely explain most of the decline.
President Donald Trump has touted more than $500 billion in prescription drug savings over 10 years from his policies. But the savings are largely aspirational, and not based on the more limited actions the administration has taken so far.
The Food and Drug Administration on March 10 changed the approval for a version of the prescription drug leucovorin to include people with a very rare genetic condition. FDA Commissioner Dr. Marty Makary had previously implied that the drug’s new label would cover a much broader group of people with autism, saying that “hundreds of thousands of kids” would benefit.
President Donald Trump has said that Americans are now paying or will pay “the lowest price anywhere in the world for drugs,” thanks to the administration’s negotiations with pharmaceutical companies. The administration has announced discounted cash prices for a small number of brand-name drugs. There isn’t evidence Trump’s deals so far have led to broad decreases in drug prices, nor is it certain they will in the future.
Voters are about to get a respite from the political attack-ad onslaught: Election Day is tomorrow. That means no more messages from Democrats attacking Republicans over abortion rights or the future of Medicare; no more Republicans blaming Democrats for inflation or crime. At least for a little while.
Political ads and social media attacks by opponents of Democratic Senate candidate John Fetterman have sought to portray Pennsylvania’s lieutenant governor as dangerously soft on crime, but some of the claims stretch the facts.